{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:05:16Z","timestamp":1787317516226,"version":"build-2736575974"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11064-019-02909-y","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T13:02:31Z","timestamp":1574254951000},"page":"1256-1267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain"],"prefix":"10.1007","volume":"45","author":[{"given":"James J.","family":"Vornov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Nedelcovych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Hollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-4157","authenticated-orcid":false,"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"3","key":"2909_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0014-2999(86)90291-8","volume":"130","author":"MB Robinson","year":"1986","unstructured":"Robinson MB, Blakely RD, Coyle JT (1986) Quisqualate selectively inhibits a brain peptidase which cleaves N-acetyl-L-aspartyl-L-glutamate in vitro. Eur J Pharmacol 130(3):345\u2013347","journal-title":"Eur J Pharmacol"},{"key":"2909_CR2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/978-1-4684-7971-3_28","volume":"203","author":"JT Coyle","year":"1986","unstructured":"Coyle JT, Blakely R, Zaczek R, Koller KJ, Abreu M, Ory-Lavollee L, Fisher R, Carpenter DO (1986) Acidic peptides in brain: do they act at putative glutamatergic synapses? Adv Exp Med Biol 203:375\u2013384. https:\/\/doi.org\/10.1007\/978-1-4684-7971-3_28","journal-title":"Adv Exp Med Biol"},{"issue":"11","key":"2909_CR3","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1073\/pnas.82.11.3897","volume":"82","author":"JM Ffrench-Mullen","year":"1985","unstructured":"Ffrench-Mullen JM, Koller K, Zaczek R, Coyle JT, Hori N, Carpenter DO (1985) N-Acetylaspartylglutamate: possible role as the neurotransmitter of the lateral olfactory tract. Proc Natl Acad Sci USA 82(11):3897\u20133900. https:\/\/doi.org\/10.1073\/pnas.82.11.3897","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2909_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/j.1471-4159.1988.tb10593.x","volume":"50","author":"RD Blakely","year":"1988","unstructured":"Blakely RD, Robinson MB, Thompson RC, Coyle JT (1988) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. J Neurochem 50(4):1200\u20131209","journal-title":"J Neurochem"},{"issue":"30","key":"2909_CR5","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1016\/S0021-9258(18)47823-4","volume":"262","author":"MB Robinson","year":"1987","unstructured":"Robinson MB, Blakely RD, Couto R, Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262(30):14498\u201314506","journal-title":"J Biol Chem"},{"issue":"34","key":"2909_CR6","doi-asserted-by":"crossref","first-page":"21297","DOI":"10.1016\/S0021-9258(17)45359-2","volume":"265","author":"BS Slusher","year":"1990","unstructured":"Slusher BS, Robinson MB, Tsai GC, Simmons ML, Richards SS, Coyle JT (1990) Rat-brain N-acetylated alpha-linked acidic dipeptidase activity\u2014purification and immunological characterization. J Biol Chem 265(34):21297\u201321301","journal-title":"J Biol Chem"},{"issue":"2","key":"2909_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/cne.903150208","volume":"315","author":"BS Slusher","year":"1992","unstructured":"Slusher BS, Tsai G, Yoo G, Coyle JT (1992) Immunocytochemical localization of the N-acetyl-aspartyl-glutamate (Naag) hydrolyzing enzyme N-acetylated alpha-linked acidic dipeptidase (Naaladase). J Comp Neurol 315(2):217\u2013229","journal-title":"J Comp Neurol"},{"issue":"2","key":"2909_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/Bf01181553","volume":"24","author":"UV Berger","year":"1995","unstructured":"Berger UV, Carter RE, Mckee M, Coyle JT (1995) N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating schwann-cells in the peripheral nervous-system. J Neurocytol 24(2):99\u2013109. https:\/\/doi.org\/10.1007\/Bf01181553","journal-title":"J Neurocytol"},{"issue":"1","key":"2909_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/(Sici)1096-9861(19991206)415:1<52::Aid-Cne4>3.0.Co;2-K","volume":"415","author":"UV Berger","year":"1999","unstructured":"Berger UV, Luthi-Carter R, Passani LA, Elkabes S, Black I, Konradi C, Coyle JT (1999) Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system. J Comp Neurol 415(1):52\u201364. https:\/\/doi.org\/10.1002\/(Sici)1096-9861(19991206)415:1%3c52:Aid-Cne4%3e3.0.Co;2-K","journal-title":"J Comp Neurol"},{"issue":"5B","key":"2909_CR10","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7(5B):927\u2013935","journal-title":"Anticancer Res"},{"issue":"2","key":"2909_CR11","first-page":"227","volume":"53","author":"RS Israeli","year":"1993","unstructured":"Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53(2):227\u2013230","journal-title":"Cancer Res"},{"issue":"7","key":"2909_CR12","first-page":"1807","volume":"54","author":"RS Israeli","year":"1994","unstructured":"Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD (1994) Expression of the prostate-specific membrane antigen. Cancer Res 54(7):1807\u20131811","journal-title":"Cancer Res"},{"issue":"3","key":"2909_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/pros.2990180305","volume":"18","author":"GE Wynant","year":"1991","unstructured":"Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdel-Nabi H et al (1991) Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate 18(3):229\u2013241","journal-title":"Prostate"},{"issue":"9","key":"2909_CR14","first-page":"1445","volume":"2","author":"JT Pinto","year":"1996","unstructured":"Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2(9):1445\u20131451","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2909_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.2910620511","volume":"62","author":"JK Troyer","year":"1995","unstructured":"Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62(5):552\u2013558","journal-title":"Int J Cancer"},{"issue":"1","key":"2909_CR16","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3(1):81\u201385","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2909_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/pros.20720","volume":"68","author":"CL Lai","year":"2008","unstructured":"Lai CL, van den Ham R, van Leenders G, van der Lugt J, Mol JA, Teske E (2008) Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate 68(5):477\u2013488. https:\/\/doi.org\/10.1002\/pros.20720","journal-title":"Prostate"},{"issue":"7","key":"2909_CR18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.117.203877","volume":"59","author":"DS O\u2019Keefe","year":"2018","unstructured":"O\u2019Keefe DS, Bacich DJ, Huang SS, Heston WDW (2018) A perspective on the evolving story of PSMA biology, PSMA-based imaging, and endoradiotherapeutic strategies. J Nucl Med 59(7):1007\u20131013. https:\/\/doi.org\/10.2967\/jnumed.117.203877","journal-title":"J Nucl Med"},{"issue":"6","key":"2909_CR19","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1046\/j.1471-4159.1997.69062270.x","volume":"69","author":"T Bzdega","year":"1997","unstructured":"Bzdega T, Turi T, Wroblewska B, She D, Chung HS, Kim H, Neale JH (1997) Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem 69(6):2270\u20132277. https:\/\/doi.org\/10.1046\/j.1471-4159.1997.69062270.x","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"2909_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0006-8993(98)00244-3","volume":"795","author":"R Luthi-Carter","year":"1998","unstructured":"Luthi-Carter R, Barczak AK, Speno H, Coyle JT (1998) Hydrolysis of the neuropeptide N-acetylaspartylglutamate (NAAG) by cloned human glutamate carboxypeptidase II. Brain Res 795(1\u20132):341\u2013348. https:\/\/doi.org\/10.1016\/s0006-8993(98)00244-3","journal-title":"Brain Res"},{"issue":"6","key":"2909_CR21","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1073\/pnas.95.6.3215","volume":"95","author":"R Luthi-Carter","year":"1998","unstructured":"Luthi-Carter R, Berger UV, Barczak AK, Enna M, Coyle JT (1998) Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 95(6):3215\u20133220. https:\/\/doi.org\/10.1073\/pnas.95.6.3215","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2909_CR22","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1073\/pnas.93.2.749","volume":"93","author":"RE Carter","year":"1996","unstructured":"Carter RE, Feldman AR, Coyle JT (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93(2):749\u2013753. https:\/\/doi.org\/10.1073\/pnas.93.2.749","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"2909_CR23","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1111\/j.1742-4658.2009.07152.x","volume":"276","author":"K Hlouchova","year":"2009","unstructured":"Hlouchova K, Barinka C, Konvalinka J, Lubkowski J (2009) Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III. FEBS J 276(16):4448\u20134462. https:\/\/doi.org\/10.1111\/j.1742-4658.2009.07152.x","journal-title":"FEBS J"},{"issue":"9","key":"2909_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2174\/092986712799462676","volume":"19","author":"K Hlouchova","year":"2012","unstructured":"Hlouchova K, Navratil V, Tykvart J, Sacha P, Konvalinka J (2012) GCPII variants, paralogs and orthologs. Curr Med Chem 19(9):1316\u20131322. https:\/\/doi.org\/10.2174\/092986712799462676","journal-title":"Curr Med Chem"},{"issue":"2","key":"2909_CR25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1021\/jm950801q","volume":"39","author":"PF Jackson","year":"1996","unstructured":"Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 39(2):619\u2013622. https:\/\/doi.org\/10.1021\/jm950801q","journal-title":"J Med Chem"},{"issue":"12","key":"2909_CR26","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/70971","volume":"5","author":"BS Slusher","year":"1999","unstructured":"Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XC, Tortella FC, Wozniak KM, Yudkoff M, Potter BM, Jackson PF (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med 5(12):1396\u20131402. https:\/\/doi.org\/10.1038\/70971","journal-title":"Nat Med"},{"issue":"6","key":"2909_CR27","doi-asserted-by":"publisher","first-page":"856","DOI":"10.2174\/092986712799034888","volume":"19","author":"C Barinka","year":"2012","unstructured":"Barinka C, Rojas C, Slusher B, Pomper M (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19(6):856\u2013870. https:\/\/doi.org\/10.2174\/092986712799034888","journal-title":"Curr Med Chem"},{"issue":"Pt 3","key":"2909_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1107\/S174430910700379X","volume":"63","author":"C Barinka","year":"2007","unstructured":"Barinka C, Starkova J, Konvalinka J, Lubkowski J (2007) A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F 63(Pt 3):150\u2013153. https:\/\/doi.org\/10.1107\/S174430910700379X","journal-title":"Acta Crystallogr Sect F"},{"issue":"Pt 4","key":"2909_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1107\/S090744490700902X","volume":"63","author":"JR Mesters","year":"2007","unstructured":"Mesters JR, Henning K, Hilgenfeld R (2007) Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr 63(Pt 4):508\u2013513. https:\/\/doi.org\/10.1107\/S090744490700902X","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"2909_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.apha.2016.01.007","volume":"76","author":"JJ Vornov","year":"2016","unstructured":"Vornov JJ, Hollinger KR, Jackson PF, Wozniak KM, Farah MH, Majer P, Rais R, Slusher BS (2016) Still NAAG\u2019ing after all these years: the continuing pursuit of GCPII inhibitors. Adv Pharmacol 76:215\u2013255. https:\/\/doi.org\/10.1016\/bs.apha.2016.01.007","journal-title":"Adv Pharmacol"},{"issue":"2","key":"2909_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1365-2125.2005.02396.x","volume":"60","author":"JP van der Post","year":"2005","unstructured":"van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, Cohen AF, van Gerven JM (2005) The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 60(2):128\u2013136. https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02396.x","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"2909_CR32","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1021\/acs.molpharmaceut.7b00231","volume":"14","author":"M Nedelcovych","year":"2017","unstructured":"Nedelcovych M, Dash RP, Tenora L, Zimmermann SC, Gadiano AJ, Garrett C, Alt J, Hollinger KR, Pommier E, Jancarik A, Rojas C, Thomas AG, Wu Y, Wozniak K, Majer P, Slusher BS, Rais R (2017) Enhanced brain delivery of 2-(Phosphonomethyl)pentanedioic acid following intranasal administration of its gamma-substituted ester prodrugs. Mol Pharm 14(10):3248\u20133257. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00231","journal-title":"Mol Pharm"},{"issue":"10","key":"2909_CR33","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1021\/acs.molpharmaceut.9b00637","volume":"16","author":"RP Dash","year":"2019","unstructured":"Dash RP, Tich\u00fd T, Veeravalli V, Lam J, Alt J, Wu Y, Tenora L, Majer P, Slusher BS, Rais R (2019) Enhanced oral bioavailability of 2-(phosphonomethyl)-pentanedioic acid (2-PMPA) from its (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (ODOL)-based prodrugs. Mol Pharm 16(10):4292\u20134301. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00637","journal-title":"Mol Pharm"},{"issue":"7","key":"2909_CR34","doi-asserted-by":"publisher","first-page":"e0131861","DOI":"10.1371\/journal.pone.0131861","volume":"10","author":"R Rais","year":"2015","unstructured":"Rais R, Wozniak K, Wu Y, Niwa M, Stathis M, Alt J, Giroux M, Sawa A, Rojas C, Slusher BS (2015) Selective CNS uptake of the GCP-II inhibitor 2-PMPA following intranasal administration. PLoS ONE 10(7):e0131861. https:\/\/doi.org\/10.1371\/journal.pone.0131861","journal-title":"PLoS ONE"},{"issue":"6","key":"2909_CR35","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","volume":"46","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche K, Turkbey B, Choyke PL (2016) PSMA PET and radionuclide therapy in prostate cancer. Sem Nuclear Med 46(6):522\u2013535. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.006","journal-title":"Sem Nuclear Med"},{"issue":"3","key":"2909_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.urolonc.2013.09.003","volume":"32","author":"BT Ristau","year":"2014","unstructured":"Ristau BT, O\u2019Keefe DS, Bacich DJ (2014) The prostate-specific membrane antigen: lessons and current clinical implications from 20\u00a0years of research. Urol Oncol 32(3):272\u2013279. https:\/\/doi.org\/10.1016\/j.urolonc.2013.09.003","journal-title":"Urol Oncol"},{"issue":"4","key":"2909_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40(4):486\u2013495. https:\/\/doi.org\/10.1007\/s00259-012-2298-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 3","key":"2909_CR38","doi-asserted-by":"publisher","first-page":"79s","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U (2016) The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med 57(Suppl 3):79s\u201389s. https:\/\/doi.org\/10.2967\/jnumed.115.170720","journal-title":"J Nucl Med"},{"issue":"7","key":"2909_CR39","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","volume":"46","author":"LM Sawicki","year":"2019","unstructured":"Sawicki LM, Kirchner J, Buddensieck C, Antke C, Ullrich T, Schimmoller L, Boos J, Schleich C, Schaarschmidt BM, Buchbender C, Heusch P, Rabenalt R, Albers P, Antoch G, Muller HW, Hautzel H (2019) Prospective comparison of whole-body MRI and (68)Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 46(7):1542\u20131550. https:\/\/doi.org\/10.1007\/s00259-019-04308-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1\u20132","key":"2909_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-017-0569-z","volume":"169","author":"C Uprimny","year":"2019","unstructured":"Uprimny C (2019) (68)Ga-PSMA-11 PET\/CT: the rising star of nuclear medicine in prostate cancer imaging? Wien Med Wochenschr 169(1\u20132):3\u201311. https:\/\/doi.org\/10.1007\/s10354-017-0569-z","journal-title":"Wien Med Wochenschr"},{"issue":"8","key":"2909_CR41","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M (2017) (177)Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med 58(8):1196\u20131200. https:\/\/doi.org\/10.2967\/jnumed.117.191023","journal-title":"J Nucl Med"},{"issue":"5","key":"2909_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, Morgenstern A (2018) Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med 59(5):795\u2013802. https:\/\/doi.org\/10.2967\/jnumed.117.203539","journal-title":"J Nucl Med"},{"key":"2909_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3895-x","author":"FE von Eyben","year":"2017","unstructured":"von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T (2017) Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-017-3895-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 2","key":"2909_CR44","doi-asserted-by":"publisher","first-page":"67s","DOI":"10.2967\/jnumed.116.186767","volume":"58","author":"M Eiber","year":"2017","unstructured":"Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL (2017) Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med 58(Suppl 2):67s\u201376s. https:\/\/doi.org\/10.2967\/jnumed.116.186767","journal-title":"J Nucl Med"},{"issue":"3","key":"2909_CR45","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00259-017-3882-2","volume":"45","author":"I Virgolini","year":"2018","unstructured":"Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C (2018) Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 45(3):471\u2013495. https:\/\/doi.org\/10.1007\/s00259-017-3882-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"2909_CR46","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U (2016) PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med 57(8):1170\u20131176. https:\/\/doi.org\/10.2967\/jnumed.115.171397","journal-title":"J Nucl Med"},{"issue":"1","key":"2909_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lutzen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bogemann M, Fendler WP, Krause BJ (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58(1):85\u201390. https:\/\/doi.org\/10.2967\/jnumed.116.183194","journal-title":"J Nucl Med"},{"key":"2909_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30198-0","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Ping Thang S, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S (2018) [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(18)30198-0","journal-title":"Lancet Oncol"},{"key":"2909_CR49","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.207993","author":"D Taieb","year":"2018","unstructured":"Taieb D, Foletti JM, Bardies M, Rocchi P, Hicks R, Haberkorn U (2018) PSMA-targeted radionuclide therapy and salivary gland toxicity: why does it matter? J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.118.207993","journal-title":"J Nucl Med"},{"issue":"13","key":"2909_CR50","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, Toklu T (2015) Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 42(13):1976\u20131983. https:\/\/doi.org\/10.1007\/s00259-015-3125-3","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2909_CR51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, Tritschler S, Stief CG, Kopka K, Haberkorn U, Bartenstein P, Boning G (2016) Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 43(1):42\u201351. https:\/\/doi.org\/10.1007\/s00259-015-3174-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2909_CR52","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U (2014) Radiation dosimetry and first therapy results with a (124)I\/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41(7):1280\u20131292. https:\/\/doi.org\/10.1007\/s00259-014-2713-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2909_CR53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.191395","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, Haberkorn U, Giesel FL, Morgenstern A (2017) Targeted alpha therapy of mCRPC with 225actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.117.191395","journal-title":"J Nucl Med"},{"issue":"6","key":"2909_CR54","doi-asserted-by":"publisher","first-page":"849","DOI":"10.7150\/thno.14744","volume":"6","author":"KL Chatalic","year":"2016","unstructured":"Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M (2016) Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent. Theranostics 6(6):849\u2013861. https:\/\/doi.org\/10.7150\/thno.14744","journal-title":"Theranostics"},{"issue":"4","key":"2909_CR55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 13(4):226\u2013235. https:\/\/doi.org\/10.1038\/nrurol.2016.26","journal-title":"Nat Rev Urol"},{"issue":"supplement 1","key":"2909_CR56","first-page":"529","volume":"59","author":"H Kulkarni","year":"2018","unstructured":"Kulkarni H, Schuchardt C, Singh A, Langbein T, Baum R (2018) Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer. J Nuclear Med 59(supplement 1):529","journal-title":"J Nuclear Med"},{"issue":"2","key":"2909_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.114.147181","volume":"56","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U (2015) PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer. J Nucl Med 56(2):293\u2013298. https:\/\/doi.org\/10.2967\/jnumed.114.147181","journal-title":"J Nucl Med"},{"issue":"9","key":"2909_CR58","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-17-1148","volume":"17","author":"KM Lemberg","year":"2018","unstructured":"Lemberg KM, Vornov JJ, Rais R, Slusher BS (2018) We\u2019re not \u201cDON\u201d yet: optimal dosing and prodrug delivery of 6-diazo-5-oxo-L-norleucine. Mol Cancer Ther 17(9):1824\u20131832. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1148","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2909_CR59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.celrep.2019.03.036","volume":"27","author":"T Nguyen","year":"2019","unstructured":"Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, Antonio MJ, Camelo F, Li T, Nguyen S, Hoang G, Nguyen K, Udupa S, Sazeides C, Shen YA, Elgogary A, Reyes J, Zhao L, Kleensang A, Chaichana KL, Hartung T, Betenbaugh MJ, Marie SK, Jung JG, Wang TL, Gabrielson E, Le A (2019) Uncovering the role of N-acetyl-aspartyl-glutamate as a glutamate reservoir in cancer. Cell Rep 27(2):491\u2013501. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.036","journal-title":"Cell Rep"},{"issue":"1","key":"2909_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215(1):159\u2013175. https:\/\/doi.org\/10.1084\/jem.20171052","journal-title":"J Exp Med"},{"issue":"13","key":"2909_CR61","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59(13):3192\u20133198","journal-title":"Cancer Res"},{"issue":"17","key":"2909_CR62","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57(17):3629\u20133634","journal-title":"Cancer Res"},{"issue":"10","key":"2909_CR63","doi-asserted-by":"publisher","first-page":"e0186280","DOI":"10.1371\/journal.pone.0186280","volume":"12","author":"LH Schmidt","year":"2017","unstructured":"Schmidt LH, Heitkotter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Gorlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S (2017) Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. PLoS ONE 12(10):e0186280. https:\/\/doi.org\/10.1371\/journal.pone.0186280","journal-title":"PLoS ONE"},{"issue":"3","key":"2909_CR64","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.18632\/oncotarget.13994","volume":"8","author":"B Heitkotter","year":"2017","unstructured":"Heitkotter B, Trautmann M, Grunewald I, Bogemann M, Rahbar K, Gevensleben H, Wardelmann E, Hartmann W, Steinestel K, Huss S (2017) Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. Oncotarget 8(3):4268\u20134276. https:\/\/doi.org\/10.18632\/oncotarget.13994","journal-title":"Oncotarget"},{"issue":"14","key":"2909_CR65","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1128\/MCB.00084-06","volume":"26","author":"RE Conway","year":"2006","unstructured":"Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26(14):5310\u20135324. https:\/\/doi.org\/10.1128\/MCB.00084-06","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2909_CR66","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10456-013-9360-y","volume":"16","author":"RE Conway","year":"2013","unstructured":"Conway RE, Joiner K, Patterson A, Bourgeois D, Rampp R, Hannah BC, McReynolds S, Elder JM, Gilfilen H, Shapiro LH (2013) Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2. Angiogenesis 16(4):847\u2013860. https:\/\/doi.org\/10.1007\/s10456-013-9360-y","journal-title":"Angiogenesis"},{"issue":"4","key":"2909_CR67","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10456-016-9521-x","volume":"19","author":"RE Conway","year":"2016","unstructured":"Conway RE, Rojas C, Alt J, Novakova Z, Richardson SM, Rodrick TC, Fuentes JL, Richardson NH, Attalla J, Stewart S, Fahmy B, Barinka C, Ghosh M, Shapiro LH, Slusher BS (2016) Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide. Angiogenesis 19(4):487\u2013500. https:\/\/doi.org\/10.1007\/s10456-016-9521-x","journal-title":"Angiogenesis"},{"issue":"5","key":"2909_CR68","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","volume":"45","author":"P Backhaus","year":"2018","unstructured":"Backhaus P, Noto B, Avramovic N, Grubert LS, Huss S, Bogemann M, Stegger L, Weckesser M, Schafers M, Rahbar K (2018) Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. Eur J Nucl Med Mol Imaging 45(5):860\u2013877. https:\/\/doi.org\/10.1007\/s00259-017-3922-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2909_CR69","doi-asserted-by":"publisher","DOI":"10.1055\/a-0914-2486","author":"M Juptner","year":"2019","unstructured":"Juptner M, Marx M, Zuhayra M, Lutzen U (2019) Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. Nuklearmedizin. https:\/\/doi.org\/10.1055\/a-0914-2486","journal-title":"Nuklearmedizin"},{"issue":"6","key":"2909_CR70","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/cancers11060833","volume":"11","author":"D Mahalingam","year":"2019","unstructured":"Mahalingam D, Peguero J, Cen P, Arora SP, Sarantopoulos J, Rowe J, Allgood V, Tubb B, Campos L (2019) A phase II, multicenter, single-arm study of mipsagargin (G-202) as a second-line therapy following sorafenib for adult patients with progressive advanced hepatocellular carcinoma. Cancers (Basel) 11(6):833. https:\/\/doi.org\/10.3390\/cancers11060833","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2909_CR71","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2867-14-26","volume":"14","author":"N Nomura","year":"2014","unstructured":"Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, Piccioni D, Juarez T, Pingle SC, Makale M, Kesari S (2014) Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell Int 14(1):26. https:\/\/doi.org\/10.1186\/1475-2867-14-26","journal-title":"Cancer Cell Int"},{"issue":"11","key":"2909_CR72","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.nucmedbio.2016.08.006","volume":"43","author":"MRA Pillai","year":"2016","unstructured":"Pillai MRA, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF (2016) Radiolabeled enzyme inhibitors and binding agents targeting PSMA: effective theranostic tools for imaging and therapy of prostate cancer. Nucl Med Biol 43(11):692\u2013720. https:\/\/doi.org\/10.1016\/j.nucmedbio.2016.08.006","journal-title":"Nucl Med Biol"},{"issue":"1","key":"2909_CR73","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00259-014-2921-5","volume":"42","author":"J Schwenck","year":"2015","unstructured":"Schwenck J, Tabatabai G, Skardelly M, Reischl G, Beschorner R, Pichler B, la Fougere C (2015) In vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol I 42(1):170\u2013171. https:\/\/doi.org\/10.1007\/s00259-014-2921-5","journal-title":"Eur J Nucl Med Mol I"},{"issue":"9","key":"2909_CR74","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","volume":"59","author":"C Rischpler","year":"2018","unstructured":"Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018) (68)Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med 59(9):1406\u20131411. https:\/\/doi.org\/10.2967\/jnumed.117.204677","journal-title":"J Nucl Med"},{"issue":"Pt 10","key":"2909_CR75","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1093\/brain\/awm199","volume":"130","author":"GJ Ebenezer","year":"2007","unstructured":"Ebenezer GJ, McArthur JC, Thomas D, Murinson B, Hauer P, Polydefkis M, Griffin JW (2007) Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 130(Pt 10):2703\u20132714. https:\/\/doi.org\/10.1093\/brain\/awm199","journal-title":"Brain"},{"issue":"4","key":"2909_CR76","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY, Haas GP (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30(4):628\u2013636. https:\/\/doi.org\/10.1007\/s00268-005-0544-5","journal-title":"World J Surg"},{"issue":"5","key":"2909_CR77","doi-asserted-by":"publisher","first-page":"e37139","DOI":"10.1371\/journal.pone.0037139","volume":"7","author":"T Zhang","year":"2012","unstructured":"Zhang T, Song B, Zhu W, Xu X, Gong QQ, Morando C, Dassopoulos T, Newberry RD, Hunt SR, Li E (2012) An ileal Crohn\u2019s disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS ONE 7(5):e37139. https:\/\/doi.org\/10.1371\/journal.pone.0037139","journal-title":"PLoS ONE"},{"issue":"2","key":"2909_CR78","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S0016-5085(75)80007-2","volume":"68","author":"CH Halsted","year":"1975","unstructured":"Halsted CH, Baugh CM, Butterworth CE Jr (1975) Jejunal perfusion of simple and conjugated folates in man. Gastroenterology 68(2):261\u2013269","journal-title":"Gastroenterology"},{"issue":"10","key":"2909_CR79","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/gut.19.10.886","volume":"19","author":"CH Halsted","year":"1978","unstructured":"Halsted CH, Reisenauer AM, Shane B, Tamura T (1978) Availability of monoglutamyl and polyglutamyl folates in normal subjects and in patients with coeliac sprue. Gut 19(10):886\u2013891","journal-title":"Gut"},{"issue":"5727","key":"2909_CR80","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/bmj.4.5727.85","volume":"4","author":"AV Hoffbrand","year":"1970","unstructured":"Hoffbrand AV, Douglas AP, Fry L, Stewart JS (1970) Malabsorption of dietary folate (Pteroylpolyglutamates) in adult coeliac disease and dermatitis herpetiformis. Br Med J 4(5727):85\u201389","journal-title":"Br Med J"},{"issue":"19","key":"2909_CR81","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/hmg\/9.19.2837","volume":"9","author":"AM Devlin","year":"2000","unstructured":"Devlin AM, Ling EH, Peerson JM, Fernando S, Clarke R, Smith AD, Halsted CH (2000) Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum Mol Genet 9(19):2837\u20132844","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2909_CR82","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0021-9150(02)00065-5","volume":"164","author":"KJ Lievers","year":"2002","unstructured":"Lievers KJ, Kluijtmans LA, Boers GH, Verhoef P, den Heijer M, Trijbels FJ, Blom HJ (2002) Influence of a glutamate carboxypeptidase II (GCPII) polymorphism (1561C\u2013\u2009>\u2009T) on plasma homocysteine, folate and vitamin B(12) levels and its relationship to cardiovascular disease risk. Atherosclerosis 164(2):269\u2013273","journal-title":"Atherosclerosis"},{"issue":"6","key":"2909_CR83","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/jn\/132.6.1176","volume":"132","author":"C Vargas-Martinez","year":"2002","unstructured":"Vargas-Martinez C, Ordovas JM, Wilson PW, Selhub J (2002) The glutamate carboxypeptidase gene II (C\u2009>\u2009T) polymorphism does not affect folate status in the Framingham Offspring cohort. J Nutr 132(6):1176\u20131179. https:\/\/doi.org\/10.1093\/jn\/132.6.1176","journal-title":"J Nutr"},{"issue":"1","key":"2909_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/jn\/133.1.75","volume":"133","author":"LA Afman","year":"2003","unstructured":"Afman LA, Trijbels FJ, Blom HJ (2003) The H475Y polymorphism in the glutamate carboxypeptidase II gene increases plasma folate without affecting the risk for neural tube defects in humans. J Nutr 133(1):75\u201377. https:\/\/doi.org\/10.1093\/jn\/133.1.75","journal-title":"J Nutr"},{"issue":"4","key":"2909_CR85","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ijc.20148","volume":"110","author":"J Chen","year":"2004","unstructured":"Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, Selhub J, Hunter DJ, Ma J (2004) Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer 110(4):617\u2013620. https:\/\/doi.org\/10.1002\/ijc.20148","journal-title":"Int J Cancer"},{"issue":"3","key":"2909_CR86","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/ajcn.83.3.708","volume":"83","author":"AM Devlin","year":"2006","unstructured":"Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH (2006) Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr 83(3):708\u2013713. https:\/\/doi.org\/10.1093\/ajcn.83.3.708","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"2909_CR87","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1093\/ajcn\/86.2.514","volume":"86","author":"CH Halsted","year":"2007","unstructured":"Halsted CH, Wong DH, Peerson JM, Warden CH, Refsum H, Smith AD, Nygard OK, Ueland PM, Vollset SE, Tell GS (2007) Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study. Am J Clin Nutr 86(2):514\u2013521. https:\/\/doi.org\/10.1093\/ajcn\/86.2.514","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2909_CR88","first-page":"3","volume":"2","author":"MM Mir","year":"2008","unstructured":"Mir MM, Dar JA, Dar NA, Dar MS, Salam I, Lone MM, Chowdary NA (2008) Combined impact of polymorphism of folate metabolism genes; glutamate carboxypeptidase, methylene tetrahydrofolate reductase and methionine synthase reductase on breast cancer susceptibility in kashmiri women. Int J Health Sci 2(1):3\u201314","journal-title":"Int J Health Sci"},{"issue":"14","key":"2909_CR89","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1111\/febs.12857","volume":"281","author":"M Navratil","year":"2014","unstructured":"Navratil M, Ptacek J, Sacha P, Starkova J, Lubkowski J, Barinka C, Konvalinka J (2014) Structural and biochemical characterization of the folyl-poly-gamma-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II. FEBS J 281(14):3228\u20133242. https:\/\/doi.org\/10.1111\/febs.12857","journal-title":"FEBS J"},{"issue":"12","key":"2909_CR90","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1097\/01.MIB.0000437045.26036.00","volume":"19","author":"S Ben-Shachar","year":"2013","unstructured":"Ben-Shachar S, Yanai H, Baram L, Elad H, Meirovithz E, Ofer A, Brazowski E, Tulchinsky H, Pasmanik-Chor M, Dotan I (2013) Gene expression profiles of ileal inflammatory bowel disease correlate with disease phenotype and advance understanding of its immunopathogenesis. Inflamm Bowel Dis 19(12):2509\u20132521. https:\/\/doi.org\/10.1097\/01.MIB.0000437045.26036.00","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2909_CR91","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ibd.21263","volume":"16","author":"CL Noble","year":"2010","unstructured":"Noble CL, Abbas AR, Lees CW, Cornelius J, Toy K, Modrusan Z, Clark HF, Arnott ID, Penman ID, Satsangi J, Diehl L (2010) Characterization of intestinal gene expression profiles in Crohn\u2019s disease by genome-wide microarray analysis. Inflamm Bowel Dis 16(10):1717\u20131728. https:\/\/doi.org\/10.1002\/ibd.21263","journal-title":"Inflamm Bowel Dis"},{"key":"2909_CR92","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88634","author":"R Rais","year":"2016","unstructured":"Rais R, Jiang W, Zhai H, Wozniak KM, Stathis M, Hollinger KR, Thomas AG, Rojas C, Vornov JJ, Marohn M, Li X, Slusher BS (2016) FOLH1\/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.88634","journal-title":"JCI Insight"},{"key":"2909_CR93","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jconrel.2017.01.036","volume":"263","author":"AA Date","year":"2017","unstructured":"Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM (2017) Local enema treatment to inhibit FOLH1\/GCPII as a novel therapy for inflammatory bowel disease. J Control Release 263:132\u2013138. https:\/\/doi.org\/10.1016\/j.jconrel.2017.01.036","journal-title":"J Control Release"},{"issue":"1","key":"2909_CR94","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/RLU.0000000000002370","volume":"44","author":"S Klingenberg","year":"2019","unstructured":"Klingenberg S, Jochumsen MR, Nielsen TF, Bouchelouche K (2019) 68Ga-PSMA uptake in anal fistula on PET\/CT scan. Clin Nucl Med 44(1):e54\u2013e56. https:\/\/doi.org\/10.1097\/RLU.0000000000002370","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2909_CR95","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/RLU.0000000000001543","volume":"42","author":"PJ Ardies","year":"2017","unstructured":"Ardies PJ, Gykiere P, Goethals L, De Mey J, De Geeter F, Everaert H (2017) PSMA uptake in mediastinal sarcoidosis. Clin Nucl Med 42(4):303\u2013305. https:\/\/doi.org\/10.1097\/RLU.0000000000001543","journal-title":"Clin Nucl Med"},{"issue":"10","key":"2909_CR96","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1097\/RLU.0000000000001310","volume":"41","author":"M Henninger","year":"2016","unstructured":"Henninger M, Maurer T, Hacker C, Eiber M (2016) 68Ga-PSMA PET\/MR showing intense psma uptake in nodular fasciitis mimicking prostate cancer metastasis. Clin Nucl Med 41(10):e443\u2013444. https:\/\/doi.org\/10.1097\/RLU.0000000000001310","journal-title":"Clin Nucl Med"},{"issue":"2","key":"2909_CR97","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/RLU.0000000000001489","volume":"42","author":"M Chan","year":"2017","unstructured":"Chan M, Hsiao E (2017) Subacute cortical infarct showing uptake on 68Ga-PSMA PET\/CT. Clin Nucl Med 42(2):110\u2013111. https:\/\/doi.org\/10.1097\/RLU.0000000000001489","journal-title":"Clin Nucl Med"},{"issue":"10","key":"2909_CR98","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1097\/RLU.0000000000001291","volume":"41","author":"B Noto","year":"2016","unstructured":"Noto B, Vrachimis A, Schafers M, Stegger L, Rahbar K (2016) Subacute stroke mimicking cerebral metastasis in 68Ga-PSMA-HBED-CC PET\/CT. Clin Nucl Med 41(10):e449\u2013451. https:\/\/doi.org\/10.1097\/RLU.0000000000001291","journal-title":"Clin Nucl Med"},{"issue":"10","key":"2909_CR99","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1097\/RLU.0000000000001340","volume":"41","author":"A Sasikumar","year":"2016","unstructured":"Sasikumar A, Joy A, Nanabala R, Pillai MR, Hari TA (2016) 68Ga-PSMA PET\/CT false-positive tracer uptake in paget disease. Clin Nucl Med 41(10):e454\u2013455. https:\/\/doi.org\/10.1097\/RLU.0000000000001340","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2909_CR100","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/RLU.0000000000002354","volume":"44","author":"E Panagiotidis","year":"2019","unstructured":"Panagiotidis E, Paschali A, Giannoula E, Chatzipavlidou V (2019) Rib fractures mimicking bone metastases in 18F-PSMA-1007 PET\/CT for prostate cancer. Clin Nucl Med 44(1):e46\u2013e48. https:\/\/doi.org\/10.1097\/RLU.0000000000002354","journal-title":"Clin Nucl Med"},{"issue":"7","key":"2909_CR101","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1097\/RLU.0000000000001672","volume":"42","author":"J Kirchner","year":"2017","unstructured":"Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, Rabenalt R, Antoch G, Buchbender C (2017) Evaluation of practical interpretation hurdles in 68Ga-PSMA PET\/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nucl Med 42(7):e322\u2013e327. https:\/\/doi.org\/10.1097\/RLU.0000000000001672","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2909_CR102","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","volume":"34","author":"M Kasoha","year":"2017","unstructured":"Kasoha M, Unger C, Solomayer E-F, Bohle RM, Zaharia C, Khreich F, Wagenpfeil S, Juhasz-B\u00f6ss I (2017) Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis 34(8):479\u2013490","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"2909_CR103","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002063","volume":"43","author":"R Kumar","year":"2018","unstructured":"Kumar R, Mittal BR, Bhattacharya A, Singh H, Singh SK (2018) Synchronous detection of male breast cancer and prostatic Cancer in a patient with suspected prostatic carcinoma on 68Ga-PSMA PET\/CT imaging. Clin Nuclear Med 43(6):431\u2013432","journal-title":"Clin Nuclear Med"},{"issue":"3","key":"2909_CR104","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","volume":"169","author":"Y Tolkach","year":"2018","unstructured":"Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik M-D, Kaiser C, Ahmadzadehfar H (2018) Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat 169(3):447\u2013455","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"2909_CR105","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/RLU.0000000000002071","volume":"43","author":"A Passah","year":"2018","unstructured":"Passah A, Arora S, Damle NA, Tripathi M, Bal C, Subudhi TK, Arora G (2018) 68Ga-prostate-specific membrane antigen PET\/CT in triple-negative breast cancer. Clin Nuclear Med 43(6):460\u2013461","journal-title":"Clin Nuclear Med"},{"issue":"5","key":"2909_CR106","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1097\/RLU.0000000000001148","volume":"41","author":"SK Taywade","year":"2016","unstructured":"Taywade SK, Damle NA, Bal C (2016) PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer? Clin Nuclear Med 41(5):e263\u2013265","journal-title":"Clin Nuclear Med"},{"issue":"3","key":"2909_CR107","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2967\/jnmt.115.171660","volume":"44","author":"S Sager","year":"2016","unstructured":"Sager S, Vatankulu B, Uslu L, S\u00f6nmezoglu K (2016) Incidental detection of follicular thyroid carcinoma in 68Ga-PSMA PET\/CT imaging. J Nuclear Med Technol 44(3):199\u2013200","journal-title":"J Nuclear Med Technol"},{"issue":"10","key":"2909_CR108","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-015-3065-y","volume":"42","author":"FA Verburg","year":"2015","unstructured":"Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF (2015) First evidence of PSMA expression in differentiated thyroid cancer using [68Ga] PSMA-HBED-CC PET\/CT. Eur J Nuclear Med Mol imaging 42(10):1622","journal-title":"Eur J Nuclear Med Mol imaging"},{"issue":"3","key":"2909_CR109","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s12032-014-0857-z","volume":"31","author":"H Ren","year":"2014","unstructured":"Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J (2014) Prostate-specific membrane antigen as a marker of pancreatic cancer cells. Med Oncol 31(3):857","journal-title":"Med Oncol"},{"issue":"5","key":"2909_CR110","doi-asserted-by":"publisher","first-page":"e0125924","DOI":"10.1371\/journal.pone.0125924","volume":"10","author":"H-l Wang","year":"2015","unstructured":"Wang H-l, Wang S-s, Song W-h, Pan Y, Yu H-p, Si T-g, Liu Y, Cui X-n, Guo Z (2015) Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS ONE 10(5):e0125924","journal-title":"PLoS ONE"},{"issue":"7","key":"2909_CR111","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/RLU.0000000000001686","volume":"42","author":"S Vamadevan","year":"2017","unstructured":"Vamadevan S, Le K, Shen L, Ha L, Mansberg R (2017) Incidental prostate-specific membrane antigen uptake in a peripheral nerve sheath tumor. Clin Nuclear Med 42(7):560\u2013562","journal-title":"Clin Nuclear Med"},{"issue":"1","key":"2909_CR112","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00259-015-3235-y","volume":"43","author":"C Rischpler","year":"2016","unstructured":"Rischpler C, Maurer T, Schwaiger M, Eiber M (2016) Intense PSMA-expression using 68Ga-PSMA PET\/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nuclear Med Mol Imaging 43(1):193","journal-title":"Eur J Nuclear Med Mol Imaging"},{"issue":"1","key":"2909_CR113","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00259-015-3236-x","volume":"43","author":"C Artigas","year":"2016","unstructured":"Artigas C, Alexiou J, Garcia C, Wimana Z, Otte F, Gil T, Van Velthoven R, Flamen P (2016) Paget bone disease demonstrated on (68)Ga-PSMA ligand PET\/CT. Eur J Nucl Med Mol Imaging 43(1):195\u2013196","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2909_CR114","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1097\/RLU.0000000000001222","volume":"41","author":"P Gykiere","year":"2016","unstructured":"Gykiere P, Goethals L, Everaert H (2016) Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET\/CT. Clin Nuclear Med 41(7):e346\u2013347","journal-title":"Clin Nuclear Med"},{"issue":"8","key":"2909_CR115","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/RLU.0000000000002156","volume":"43","author":"S Hober\u00fcck","year":"2018","unstructured":"Hober\u00fcck S, Michler E, Kaiser D, R\u00f6hnert A, Z\u00f6phel K, Kotzerke J (2018) Prostate-specific membrane antigen expression in distal radius fracture. Clin Nuclear Med 43(8):611\u2013613","journal-title":"Clin Nuclear Med"},{"issue":"9","key":"2909_CR116","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00259-017-3712-6","volume":"44","author":"L De Coster","year":"2017","unstructured":"De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, Pans S, Van Laere K, Goffin KE (2017) Fibrous dysplasia mimicking bone metastasis on 68 GA-PSMA PET\/MRI. Eur J Nuclear Med Mol Imaging 44(9):1607\u20131608","journal-title":"Eur J Nuclear Med Mol Imaging"},{"issue":"7","key":"2909_CR117","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1097\/RLU.0000000000001672","volume":"42","author":"J Kirchner","year":"2017","unstructured":"Kirchner J, Schaarschmidt BM, Sawicki LM, Heusch P, Hautzel H, Ermert J, Rabenalt R, Antoch G, Buchbender C (2017) Evaluation of practical interpretation hurdles in 68Ga-PSMA PET\/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin Nuclear Med 42(7):e322\u2013e327","journal-title":"Clin Nuclear Med"},{"issue":"11","key":"2909_CR118","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1097\/RLU.0000000000000827","volume":"40","author":"C Kobe","year":"2015","unstructured":"Kobe C, Maintz D, Fischer T, Drzezga A, Chang D-H (2015) Prostate-specific membrane antigen PET\/CT in splenic sarcoidosis. Clin Nuclear Med 40(11):897\u2013898","journal-title":"Clin Nuclear Med"},{"issue":"10","key":"2909_CR119","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.1097\/RLU.0000000000001291","volume":"41","author":"B Noto","year":"2016","unstructured":"Noto B, Vrachimis A, Sch\u00e4fers M, Stegger L, Rahbar K (2016) Subacute stroke mimicking cerebral metastasis in 68Ga-PSMA-HBED-CC PET\/CT. Clin Nuclear Med 41(10):e449\u2013451","journal-title":"Clin Nuclear Med"},{"issue":"2","key":"2909_CR120","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/RLU.0000000000001948","volume":"43","author":"G Oh","year":"2018","unstructured":"Oh G, Miles K (2018) Subacute cerebellar infarction with uptake on 68Ga-prostate-specific membrane antigen PET\/CT. Clin Nuclear Med 43(2):134\u2013135","journal-title":"Clin Nuclear Med"},{"issue":"6","key":"2909_CR121","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/RLU.0000000000001650","volume":"42","author":"GG Daglioz","year":"2017","unstructured":"Daglioz GG, Hekimsoy T, Isgoren S, Sikar AA, Demir H (2017) Uptake of an acrochordon incidentally detected on 68Ga prostate-specific membrane antigen PET\/CT. Clin Nuclear Med 42(6):461\u2013462","journal-title":"Clin Nuclear Med"},{"issue":"12","key":"2909_CR122","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/modpathol.2008.143","volume":"21","author":"IO Gordon","year":"2008","unstructured":"Gordon IO, Tretiakova MS, Noffsinger AE, Hart J, Reuter VE, Al-Ahmadie HA (2008) Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol 21(12):1421","journal-title":"Mod Pathol"},{"issue":"6","key":"2909_CR123","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/RLU.0000000000001192","volume":"41","author":"GL Kanthan","year":"2016","unstructured":"Kanthan GL, Hsiao E, Kneebone A, Eade T, Schembri GP (2016) Desmoid tumor showing intense uptake on 68Ga PSMA-HBED-CC PET\/CT. Clin Nuclear Med 41(6):508\u2013509","journal-title":"Clin Nuclear Med"},{"issue":"9","key":"2909_CR124","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","volume":"59","author":"C Rischpler","year":"2018","unstructured":"Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, Gschwend J, Maurer T, Meyer PT, Eiber M (2018) 68Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nuclear Med 59(9):1406\u20131411","journal-title":"J Nuclear Med"},{"issue":"6","key":"2909_CR125","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/RLU.0000000000001654","volume":"42","author":"HD Zacho","year":"2017","unstructured":"Zacho HD, Nielsen JB, Dettmann K, Hjulskov SH, Petersen LJ (2017) 68Ga-PSMA PET\/CT uptake in intramuscular myxoma imitates prostate cancer metastasis. Clin Nuclear Med 42(6):487\u2013488","journal-title":"Clin Nuclear Med"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-019-02909-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-019-02909-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-019-02909-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T09:59:22Z","timestamp":1612432762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-019-02909-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["2909"],"URL":"https:\/\/doi.org\/10.1007\/s11064-019-02909-y","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"15 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}